Perbedaan Kadar Deoxypyridinoline pada Wanita Reproduktif Pasca Injeksi GnRH Agonis dan Tanpa Injeksi GnRH Agonis
DAFTAR PUSTAKA
1.
M.A.F. Youssef, Hatem I. Abdelmoty, Mohamed A.S. Ahmed, Maged
Elmohamady. GnRH agonis for final oocyte maturation in GnRH antagonis cotreated IVF/ICSI treatment cycles: Systematic review and meta-analysis, Journal
of Advanced Research, Volume 6, Issue 3, May 2015, Pages 341-349, ISSN
2090-1232, http://dx.doi.org/10.1016/j.jare.2015.01.005.
2.
Tanaka et al. Results of Long-Term Follow-Up after Treatment of Central
Precocious Puberty with Leuprorelin Acetate: Evaluation of Effectiveness of
Treatment and Recovery of Gonadal Function. The TAP-144-SR Japanese Study
Group on Central Precocious Puberty. The Journal of Clinical Endocrinology &
Metabolism Volume 90, Issue 3. Avalibale from: http://dx.doi.org/10.1210/jc.2004.
3.
Sarmidi S, Setiyohadi B, dan Anggoro S. Vitamin D Status and
Hyperparathyroidism in Postmenopausal Osteoporotic Patient in Cipto
Mangunkusumo Hospital Jakarta. Indones J Intern Med. 2008.
4.
Daniele ND, Carbonelli MG, Candeloro N, Iacopino L, De Lorenzo A, dan
Andreoli A. Effect of supplementation of calcium and Vitamin D on bone mineral
density and bone mineral content in peri- and post-menopause women A doubleblind, randomized, controlled trial. Pharmacological Res 2004; 50: 637-641.
5.
Klaus Jung, Michael Lein. Bone turnover markers in serum and urine as
diagnostic, prognostic and monitoring biomarkers of bone metastasis, Biochimica
et Biophysica Acta (BBA) - Reviews on Cancer, Volume 1846, Issue 2,
December
2014,
Pages
425-438,
ISSN
0304-419X,
http://dx.doi.org/10.1016/j.bbcan.2014.09.001
6.
Jiandang Shi, Zili Wang, Haomin Li, dan Haifeng Yuan. Diagnostic Performance
of the Urinary Deoxypyridinoline in Spinal Tuberculosis. Healio.com The new
online home of Orthopedics, June2012, Volume 35, Number 6.
7.
R. Thompson, Ursula B. Kaiser. GnRH pulse frequency-dependent differential
regulation of LH and FSH gene expression, Molecular and Cellular
Endocrinology, Volume 385, Issues 1–2, 25 March 2014, Pages 28-35, ISSN
0303-7207, http://dx.doi.org/10.1016/j.mce.2013.09.012.
8.
Constantin S. Physiology of the GnRH neuron : Studies from embryonic GnRH
neurons. J Neuroendocrinol . 2011 June ; 23(6): 542–553.
9.
Susanna Röblitz, Claudia Stötzel, Peter Deuflhard, Hannah M. Jones, DavidOlivier Azulay, Piet H. van der Graaf, Steven W. Martin. A mathematical model of
the human menstrual cycle for the administration of GnRH analogues, Journal of
Theoretical Biology, Volume 321, 21 March 2013, Pages 8-27, ISSN 0022-5193,
http://dx.doi.org/10.1016/j.jtbi.2012.11.020.
41
Universitas Sumatera Utara
10. Matthew Prideaux, David M Findlay, Gerald J Atkins. Osteocytes: The master
cells in bone remodelling, Current Opinion in Pharmacology, Volume 28, 2016,
Pages 24-30, ISSN 1471-4892, http://dx.doi.org/10.1016/j.coph.2016.02.003.
11. NIH Consensus Statement.Osteoporosis Prevention, Diagnosis and Therapy.
March, 2000 27-29;17(1):1-45.
12. World Health Organization. WHO Scientific Group on the Assessment of
Osteoporosis at Primary Health Care Level. Summary Meeting Report. Belgium
2004.
13. Speroff L, Glass RH, dan Kase NG. Neuroendocrinology. In: Clinical
Gynecologic Endocrinology and Infertility. Fifth Edition. William & Wilkins,
Baltimore-USA, 2010; 5 :141-82.
14. NAMS Continuing Medical Education Activity. Management of Osteoporosis in
Postmenopausal Women: 2010 Position Statement of The North American
Menopause Society. Vol.17 No.1,pp 23-24.
15. Putra, Irwansyah. 2010. Studi Banding Densitas Mineral Tulang pada Masa
Klimakterum. Universitas Sumatera Utara.
16. Mundi, J.S., Cabalero, F.J.C., Abadia, H.C., dan Ibnes, J.J.M. Bone massa
density and serum levels of soluble TNF, estradiol and osteoprotegerin in
postmenopause women. Journal of clinical endocrinology and metabolism. 2009;
Vol. 94 No. 12:4844-50.
17. Lerner UH, dkk. Bone remodeling in post-menopausal osteoporosis. J Dent Res
85,2006:584-595.
18. Clarke BL, Khosia S. Physiology of Bone Loss. Radiol Clin North Am. 2010;
48(3): 483-95.
19. Baziad, Ali. Menopause dan Andropause. Yayasan Bina Pustaka Sarwono
Prawirohardjo. Juni 2003.
20. V. Savica, G. Bellinghieri, P. Monardo, U. Muraca, dan D. Santoro. An update on
calcium metabolism alterations and cardiovascular risk in patients with chronic
kidney disease: questions, myths and fact. Journal of Nephrology, vol. 26, no. 3,
pp. 456–464, 2013.
21. Aysha B. Khalid, Susan A. Krum. Estrogen receptors alpha and beta in bone.
Volume
87,
2016,
Pages
130-135,
ISSN
8756-3282,
http://dx.doi.org/10.1016/j.bone.2016.03.016.
22. Lucisano MP, Filho PN, Morse L, Battaglino R, Watanabe PC, dan Silva RA.
Radiodensitometric and DXA analyses for the measurement of bone mineral
density after systemic alendronate therapy. Braz Oral 2013; 27(3): 1-5.
42
Universitas Sumatera Utara
23. Victor Hng Hang Goh, William George Hart. Aging and bone health in
Singaporean Chinese pre-menopausal and postmenopausal women, Maturitas,
Volume 89, 2016, Pages 16-21, ISSN 0378-5122.
24. Aboelasrar MA, Elbarbary NS, Elshennawy DE, dan Omar AM. Insulin-like
growth factor-1 cytokines cross-talk in type 1 diabetes mellitus: relationship to
microvascular complications and bone mineral density. Cytokine. 2012
Jul;59(1):86-93.
25. Canadian Association of radiologist. Bone mineral densitometry reporting. CAR
2013.
26. Gass B, Hughes BD. Preventing Osteoporosis-related Fracture : an Overview.
The American Journal of Medicine. Volume 119, Issue 4, Apr 2006.
27. Stancyzk FZ, Jurow J, dan Hsing AW. Limitations of Direct Immunoassays for
Measuring Circulating Estradiol Levels in Postmenopausal Women and Men in
Epidemiologic Studies. Cancer Epidemiol Biomarkers Prev April 2010 19; 903.
28. Wahdi, Pramono N, dan Hidayat ST. Kadar Estradiol Serum Pada Wanita
Menopause Dengan Dan Tanpa Sindroma Vasomotor. Departemen Obstetri dan
Ginekologi Fakultas Kedokteran Universitas Diponogoro, Semarang, 2003.
29. Myra Barginear, Anne Clotfelter, Catherine Van Poznak. Markers of Bone
Metabolism in Women Receiving Aromatase Inhibitors for Early-Stage Breast
Cancer, Clinical Breast Cancer, Volume 9, Issue 2, May 2009, Pages 72-76,
ISSN 1526-8209, http://dx.doi.org/10.3816/CBC.2009.n.014.
30. Xiong-Wen Zhou, Xi-Yu Wu, Lin Luo, Li-Juan Guo, Ming-Xiang Lei, Hong Zhang,
Hui Xie, Yi-Qun Peng, Xian-Ping Wu, Er-Yuan Liao. The relationship between
bone turnover markers and BMD decreasing rates in Chinese middle-aged
women, Clinica Chimica Acta, Volume 412, Issues 17–18, 17 August 2011,
Pages 1648-1657, ISSN 0009-8981, http://dx.doi.org/10.1016/j.cca.2011.05.020.
31. Miriam F. Delaney. Strategies for the prevention and treatment of osteoporosis
during early postmenopause, American Journal of Obstetrics and Gynecology,
Volume 194, Issue 2, Supplement, February 2006, Pages S12-S23, ISSN 00029378, http://dx.doi.org/10.1016/j.ajog.2005.08.049.
32. Alan L. Burshell, Rüdiger Möricke, Ricardo Correa-Rotter, Peiqi Chen, Margaret
R. Warner, Gail P. Dalsky, Kathleen A. Taylor, John H. Krege. Correlations
between biochemical markers of bone turnover and bone density responses in
patients with glucocorticoid-induced osteoporosis treated with teriparatide or
alendronate, Bone, Volume 46, Issue 4, April 2010, Pages 935-939, ISSN 87563282, http://dx.doi.org/10.1016/j.bone.2009.12.032.
33. Fernando Rivadeneira, Outi Mäkitie. Osteoporosis and Bone Mass Disorders:
From Gene Pathways to Treatments, Trends in Endocrinology & Metabolism,
43
Universitas Sumatera Utara
Volume 27, Issue 5, 2016, Pages
http://dx.doi.org/10.1016/j.tem.2016.03.006.
262-281,
ISSN
1043-2760,
34. Johnell, O., & Kanis, J. A. (2006). An estimate of the worldwide prevalence and
disability associated with osteoporotic fractures. Osteoporosis international,
17(12), 1726-1733.
35. Siregar MFG, Siburian PS, Kaban YB, at al. The differences of catalase enzyme
level between menopause and reproductive women. Giorn.It. Ost. Gin. Vol
XXXVII-n.6. November – December 2015.
36. Mezquita-Raya, P., de la Higuera, M., García, D. F., Alonso, G., Ruiz-Requena,
M. E., de Dios Luna, J., & Munoz-Torres, M. (2005). The contribution of serum
osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
Osteoporosis international, 16(11), 1368-1374.
37. Mori, T., Ishii, S., Greendale, G. A., Cauley, J. A., Ruppert, K., Crandall, C. J., &
Karlamangla, A. S. (2015). Parity, lactation, bone strength, and 16-year fracture
risk in adult women: Findings from the Study of Women's Health Across the
Nation (SWAN). Bone, 73, 160-166.
38. Pietro Allevi, Eti Alessandra Femia, Paola Rota, Maria Letizia Costa, Mario
Anastasia, Synthesis of unnatural homologues of Deoxypyridinoline as possible
internal standards in analytical detection of pyridinolinic cross-links of collagen,
Tetrahedron: Asymmetry, Volume 19, Issue 21, 3 November 2008, Pages 24702478, ISSN 0957-4166, http://dx.doi.org/10.1016/j.tetasy.2008.11.001.
39. Ersoy, G. S., Giray, B., Subas, S., et al Interpregnancy interval as a risk factor for
postmenopausal osteoporosis. Maturitas. (2015). 82(2), 236-240.
40. Patrick Garnero. New developments in biological markers of bone metabolism in
osteoporosis, Bone, Volume 66, September 2014, Pages 46-55, ISSN 87563282, http://dx.doi.org/10.1016/j.bone.2014.05.016.
41. Amama EA. Taga M, Minaguchi H. The Effect of Gonadotropin Releasing
Hormone Agonist on Type I Collagen C-Telopeptide and N Telopeptide: the
Predictive Value of Biochemical Markers of Bone Turnover. Journal of Clinical
Endocrinology and Metabolism 1998 by The Endocrine Society. Vol 8. No 2.
Department of Obstetric and Gynecology. Yokohama city University School of
Medicine Kanazawa-ku, Yokohama, 236 Japan.
42. Divasta AD, Laufer MA, Gordon CM. Bone Density in Adolescence Treated with
GnRH Agonist and Add Back Therapy fpr Endometriosis. J Pediatric Adolesc
Gynecol. 2007 October;20 (5):293-297.
43. Lee SJ, Yang E M, Seo JY et all. Effect of Gonadotropin Releasing Hormone
Agonist Therapy on Body Mass Index and Height in Girls With Central
Precocciious Puberty. Department of Paediatrics, Chonnam National University
Medical School, Guanju, Korea. 2012.
44
Universitas Sumatera Utara
1.
M.A.F. Youssef, Hatem I. Abdelmoty, Mohamed A.S. Ahmed, Maged
Elmohamady. GnRH agonis for final oocyte maturation in GnRH antagonis cotreated IVF/ICSI treatment cycles: Systematic review and meta-analysis, Journal
of Advanced Research, Volume 6, Issue 3, May 2015, Pages 341-349, ISSN
2090-1232, http://dx.doi.org/10.1016/j.jare.2015.01.005.
2.
Tanaka et al. Results of Long-Term Follow-Up after Treatment of Central
Precocious Puberty with Leuprorelin Acetate: Evaluation of Effectiveness of
Treatment and Recovery of Gonadal Function. The TAP-144-SR Japanese Study
Group on Central Precocious Puberty. The Journal of Clinical Endocrinology &
Metabolism Volume 90, Issue 3. Avalibale from: http://dx.doi.org/10.1210/jc.2004.
3.
Sarmidi S, Setiyohadi B, dan Anggoro S. Vitamin D Status and
Hyperparathyroidism in Postmenopausal Osteoporotic Patient in Cipto
Mangunkusumo Hospital Jakarta. Indones J Intern Med. 2008.
4.
Daniele ND, Carbonelli MG, Candeloro N, Iacopino L, De Lorenzo A, dan
Andreoli A. Effect of supplementation of calcium and Vitamin D on bone mineral
density and bone mineral content in peri- and post-menopause women A doubleblind, randomized, controlled trial. Pharmacological Res 2004; 50: 637-641.
5.
Klaus Jung, Michael Lein. Bone turnover markers in serum and urine as
diagnostic, prognostic and monitoring biomarkers of bone metastasis, Biochimica
et Biophysica Acta (BBA) - Reviews on Cancer, Volume 1846, Issue 2,
December
2014,
Pages
425-438,
ISSN
0304-419X,
http://dx.doi.org/10.1016/j.bbcan.2014.09.001
6.
Jiandang Shi, Zili Wang, Haomin Li, dan Haifeng Yuan. Diagnostic Performance
of the Urinary Deoxypyridinoline in Spinal Tuberculosis. Healio.com The new
online home of Orthopedics, June2012, Volume 35, Number 6.
7.
R. Thompson, Ursula B. Kaiser. GnRH pulse frequency-dependent differential
regulation of LH and FSH gene expression, Molecular and Cellular
Endocrinology, Volume 385, Issues 1–2, 25 March 2014, Pages 28-35, ISSN
0303-7207, http://dx.doi.org/10.1016/j.mce.2013.09.012.
8.
Constantin S. Physiology of the GnRH neuron : Studies from embryonic GnRH
neurons. J Neuroendocrinol . 2011 June ; 23(6): 542–553.
9.
Susanna Röblitz, Claudia Stötzel, Peter Deuflhard, Hannah M. Jones, DavidOlivier Azulay, Piet H. van der Graaf, Steven W. Martin. A mathematical model of
the human menstrual cycle for the administration of GnRH analogues, Journal of
Theoretical Biology, Volume 321, 21 March 2013, Pages 8-27, ISSN 0022-5193,
http://dx.doi.org/10.1016/j.jtbi.2012.11.020.
41
Universitas Sumatera Utara
10. Matthew Prideaux, David M Findlay, Gerald J Atkins. Osteocytes: The master
cells in bone remodelling, Current Opinion in Pharmacology, Volume 28, 2016,
Pages 24-30, ISSN 1471-4892, http://dx.doi.org/10.1016/j.coph.2016.02.003.
11. NIH Consensus Statement.Osteoporosis Prevention, Diagnosis and Therapy.
March, 2000 27-29;17(1):1-45.
12. World Health Organization. WHO Scientific Group on the Assessment of
Osteoporosis at Primary Health Care Level. Summary Meeting Report. Belgium
2004.
13. Speroff L, Glass RH, dan Kase NG. Neuroendocrinology. In: Clinical
Gynecologic Endocrinology and Infertility. Fifth Edition. William & Wilkins,
Baltimore-USA, 2010; 5 :141-82.
14. NAMS Continuing Medical Education Activity. Management of Osteoporosis in
Postmenopausal Women: 2010 Position Statement of The North American
Menopause Society. Vol.17 No.1,pp 23-24.
15. Putra, Irwansyah. 2010. Studi Banding Densitas Mineral Tulang pada Masa
Klimakterum. Universitas Sumatera Utara.
16. Mundi, J.S., Cabalero, F.J.C., Abadia, H.C., dan Ibnes, J.J.M. Bone massa
density and serum levels of soluble TNF, estradiol and osteoprotegerin in
postmenopause women. Journal of clinical endocrinology and metabolism. 2009;
Vol. 94 No. 12:4844-50.
17. Lerner UH, dkk. Bone remodeling in post-menopausal osteoporosis. J Dent Res
85,2006:584-595.
18. Clarke BL, Khosia S. Physiology of Bone Loss. Radiol Clin North Am. 2010;
48(3): 483-95.
19. Baziad, Ali. Menopause dan Andropause. Yayasan Bina Pustaka Sarwono
Prawirohardjo. Juni 2003.
20. V. Savica, G. Bellinghieri, P. Monardo, U. Muraca, dan D. Santoro. An update on
calcium metabolism alterations and cardiovascular risk in patients with chronic
kidney disease: questions, myths and fact. Journal of Nephrology, vol. 26, no. 3,
pp. 456–464, 2013.
21. Aysha B. Khalid, Susan A. Krum. Estrogen receptors alpha and beta in bone.
Volume
87,
2016,
Pages
130-135,
ISSN
8756-3282,
http://dx.doi.org/10.1016/j.bone.2016.03.016.
22. Lucisano MP, Filho PN, Morse L, Battaglino R, Watanabe PC, dan Silva RA.
Radiodensitometric and DXA analyses for the measurement of bone mineral
density after systemic alendronate therapy. Braz Oral 2013; 27(3): 1-5.
42
Universitas Sumatera Utara
23. Victor Hng Hang Goh, William George Hart. Aging and bone health in
Singaporean Chinese pre-menopausal and postmenopausal women, Maturitas,
Volume 89, 2016, Pages 16-21, ISSN 0378-5122.
24. Aboelasrar MA, Elbarbary NS, Elshennawy DE, dan Omar AM. Insulin-like
growth factor-1 cytokines cross-talk in type 1 diabetes mellitus: relationship to
microvascular complications and bone mineral density. Cytokine. 2012
Jul;59(1):86-93.
25. Canadian Association of radiologist. Bone mineral densitometry reporting. CAR
2013.
26. Gass B, Hughes BD. Preventing Osteoporosis-related Fracture : an Overview.
The American Journal of Medicine. Volume 119, Issue 4, Apr 2006.
27. Stancyzk FZ, Jurow J, dan Hsing AW. Limitations of Direct Immunoassays for
Measuring Circulating Estradiol Levels in Postmenopausal Women and Men in
Epidemiologic Studies. Cancer Epidemiol Biomarkers Prev April 2010 19; 903.
28. Wahdi, Pramono N, dan Hidayat ST. Kadar Estradiol Serum Pada Wanita
Menopause Dengan Dan Tanpa Sindroma Vasomotor. Departemen Obstetri dan
Ginekologi Fakultas Kedokteran Universitas Diponogoro, Semarang, 2003.
29. Myra Barginear, Anne Clotfelter, Catherine Van Poznak. Markers of Bone
Metabolism in Women Receiving Aromatase Inhibitors for Early-Stage Breast
Cancer, Clinical Breast Cancer, Volume 9, Issue 2, May 2009, Pages 72-76,
ISSN 1526-8209, http://dx.doi.org/10.3816/CBC.2009.n.014.
30. Xiong-Wen Zhou, Xi-Yu Wu, Lin Luo, Li-Juan Guo, Ming-Xiang Lei, Hong Zhang,
Hui Xie, Yi-Qun Peng, Xian-Ping Wu, Er-Yuan Liao. The relationship between
bone turnover markers and BMD decreasing rates in Chinese middle-aged
women, Clinica Chimica Acta, Volume 412, Issues 17–18, 17 August 2011,
Pages 1648-1657, ISSN 0009-8981, http://dx.doi.org/10.1016/j.cca.2011.05.020.
31. Miriam F. Delaney. Strategies for the prevention and treatment of osteoporosis
during early postmenopause, American Journal of Obstetrics and Gynecology,
Volume 194, Issue 2, Supplement, February 2006, Pages S12-S23, ISSN 00029378, http://dx.doi.org/10.1016/j.ajog.2005.08.049.
32. Alan L. Burshell, Rüdiger Möricke, Ricardo Correa-Rotter, Peiqi Chen, Margaret
R. Warner, Gail P. Dalsky, Kathleen A. Taylor, John H. Krege. Correlations
between biochemical markers of bone turnover and bone density responses in
patients with glucocorticoid-induced osteoporosis treated with teriparatide or
alendronate, Bone, Volume 46, Issue 4, April 2010, Pages 935-939, ISSN 87563282, http://dx.doi.org/10.1016/j.bone.2009.12.032.
33. Fernando Rivadeneira, Outi Mäkitie. Osteoporosis and Bone Mass Disorders:
From Gene Pathways to Treatments, Trends in Endocrinology & Metabolism,
43
Universitas Sumatera Utara
Volume 27, Issue 5, 2016, Pages
http://dx.doi.org/10.1016/j.tem.2016.03.006.
262-281,
ISSN
1043-2760,
34. Johnell, O., & Kanis, J. A. (2006). An estimate of the worldwide prevalence and
disability associated with osteoporotic fractures. Osteoporosis international,
17(12), 1726-1733.
35. Siregar MFG, Siburian PS, Kaban YB, at al. The differences of catalase enzyme
level between menopause and reproductive women. Giorn.It. Ost. Gin. Vol
XXXVII-n.6. November – December 2015.
36. Mezquita-Raya, P., de la Higuera, M., García, D. F., Alonso, G., Ruiz-Requena,
M. E., de Dios Luna, J., & Munoz-Torres, M. (2005). The contribution of serum
osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
Osteoporosis international, 16(11), 1368-1374.
37. Mori, T., Ishii, S., Greendale, G. A., Cauley, J. A., Ruppert, K., Crandall, C. J., &
Karlamangla, A. S. (2015). Parity, lactation, bone strength, and 16-year fracture
risk in adult women: Findings from the Study of Women's Health Across the
Nation (SWAN). Bone, 73, 160-166.
38. Pietro Allevi, Eti Alessandra Femia, Paola Rota, Maria Letizia Costa, Mario
Anastasia, Synthesis of unnatural homologues of Deoxypyridinoline as possible
internal standards in analytical detection of pyridinolinic cross-links of collagen,
Tetrahedron: Asymmetry, Volume 19, Issue 21, 3 November 2008, Pages 24702478, ISSN 0957-4166, http://dx.doi.org/10.1016/j.tetasy.2008.11.001.
39. Ersoy, G. S., Giray, B., Subas, S., et al Interpregnancy interval as a risk factor for
postmenopausal osteoporosis. Maturitas. (2015). 82(2), 236-240.
40. Patrick Garnero. New developments in biological markers of bone metabolism in
osteoporosis, Bone, Volume 66, September 2014, Pages 46-55, ISSN 87563282, http://dx.doi.org/10.1016/j.bone.2014.05.016.
41. Amama EA. Taga M, Minaguchi H. The Effect of Gonadotropin Releasing
Hormone Agonist on Type I Collagen C-Telopeptide and N Telopeptide: the
Predictive Value of Biochemical Markers of Bone Turnover. Journal of Clinical
Endocrinology and Metabolism 1998 by The Endocrine Society. Vol 8. No 2.
Department of Obstetric and Gynecology. Yokohama city University School of
Medicine Kanazawa-ku, Yokohama, 236 Japan.
42. Divasta AD, Laufer MA, Gordon CM. Bone Density in Adolescence Treated with
GnRH Agonist and Add Back Therapy fpr Endometriosis. J Pediatric Adolesc
Gynecol. 2007 October;20 (5):293-297.
43. Lee SJ, Yang E M, Seo JY et all. Effect of Gonadotropin Releasing Hormone
Agonist Therapy on Body Mass Index and Height in Girls With Central
Precocciious Puberty. Department of Paediatrics, Chonnam National University
Medical School, Guanju, Korea. 2012.
44
Universitas Sumatera Utara